Bianchi Francesco Paolo, De Nitto Sara, Stefanizzi Pasquale, Larocca Angela Maria Vittoria, Germinario Cinzia Annatea, Tafuri Silvio
Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari , Bari, Italy.
Hygiene Department, Bari Policlinico General Hospital , Bari, Italy.
Hum Vaccin Immunother. 2020 Nov 1;16(11):2649-2655. doi: 10.1080/21645515.2020.1735861. Epub 2020 Mar 18.
Protective levels of antibodies induced by the MMR vaccine have been shown to decline over time, but actually there is not a formal recommendation about the opportunity of testing immunized HCWs to investigate the persistence of anti-Mumps IgG. This study aims to evaluate the long-time immunogenicity of MMR vaccination in a sample of medical students and residents of the University of Bari who attended the Hygiene Department for the biological risk assessment (April 2014-June 2018). A strategy for the management of non-responder subjects has been experimented and described. Two thousand students and residents, with documented immunization status (two doses of MMR vaccine), have been tested. 120/2,000 (6%; 95%CI = 5.0-7.1%) subjects did not show anti-Mumps IgG. This percentage was similar among males and females. After a third MMR dose, we noted a seroconversion of 90% of seronegative participants. No serious adverse events were recorded. An important proportion of subjects immunized for MMR do not show an antibodies protective titer. The immunogenicity and the safety of the third dose seem confirmed by our data. Including the screening model described in the routine assessment of the biological risk of medical students and HCWs may be a winning strategy in preventing Mumps nosocomial infection.
MMR疫苗诱导产生的抗体保护水平已被证明会随时间下降，但实际上对于检测已接种疫苗的医护人员以调查抗腮腺炎IgG抗体持久性的时机，并没有正式的建议。本研究旨在评估巴里大学医学院学生和住院医师样本中MMR疫苗接种的长期免疫原性，这些人员于2014年4月至2018年6月前往卫生部门进行生物风险评估。我们试验并描述了一种针对无反应者的管理策略。对2000名有疫苗接种记录（两剂MMR疫苗）的学生和住院医师进行了检测。120/2000（6%；95%CI = 5.0 - 7.1%）名受试者未检测到抗腮腺炎IgG。该比例在男性和女性中相似。在接种第三剂MMR疫苗后，我们注意到90%的血清阴性参与者出现了血清转化。未记录到严重不良事件。相当一部分接种MMR疫苗的受试者未显示出抗体保护滴度。我们的数据似乎证实了第三剂疫苗的免疫原性和安全性。在医学生和医护人员的生物风险常规评估中纳入所述筛查模型，可能是预防腮腺炎医院感染的成功策略。
